Privo Technologies Announces the Appointment of Dr. James Mackay to Its Board of Directors
Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment of Dr. James Mackay to Its Board of Directors.
BOSTON, June 30, 2020 (Newswire.com) - Dr. Mackay joins the Board of Directors of Privo Technologies with over 30 years of experience in the development of pharmaceuticals, and a strong record of bringing multiple drugs to market and patients.
Dr. Mackay is the founder, president, and CEO of Aristea Therapeutics, an immunology company focused on developing treatments for orphan diseases. Prior to founding Aristea Therapeutics, Dr. Mackay led the successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca. He was President & CEO of Ardea Biosciences from 2013 to 2018. He set up an innovative model for Ardea that retained the biotech’s independence and accountability for the development of the gout franchise while developing a collaborative relationship with the parent company, AstraZeneca.
Prior to Ardea Biosciences, Dr. Mackay was Global Product Vice President for Diabetes franchise at AstraZeneca where he played a critical role in the successful development of the AstraZeneca/Bristol-Myers Squibb diabetes alliance. He held a number of senior roles in AstraZeneca’s Clinical Development Function including portfolio management of all AstraZeneca Clinical resources and budget worldwide and management of AstraZeneca’s strategic partnerships with drug development CROs.
“On behalf of Privo Technologies and the Board of Directors, I welcome James as we look forward to drawing upon his strategic, operational, and clinical judgment,” said Manijeh Goldberg, Founder, and CEO of Privo Technologies. “We are thrilled to team up with him at a critical time in our evolution as we advance our lead program through Phase 3. His significant insights and experience running large pharmaceutical and small biotechnology businesses will be essential while we continue to strengthen the development of our oncology platform technology.”
“I am delighted to have the opportunity to join the Privo Technologies Board of Directors at such a critical time for the company as we move through Phase 3 clinical development. The targeted nanotechnology platform (PRVTM) for cancer therapy that Privo has developed is ground-breaking and I look forward to working with the management team to develop the Privo PRVTM products through to regulatory approval and look forward to seeing them make a meaningful difference to the lives of cancer patients,” said Dr. Mackay.
About Privo Technologies:
Privo is a private clinical-stage oncology company with proven nanotechnology that is capable of local and regional chemotherapy and strong immunomodulation. Its PRV111™ is a topically administered therapy that targets the tumor and regional lymph nodes. In a phase 2 clinical study of patients with head and neck cancer, PRV111 has shown over 70% reduction of tumor volume in more than 85% of patients in 1 week. Patients did not experience any dose-limiting toxicities and none discontinued study treatment due to adverse events.
Privo intends to use this treatment for intra-operative chemotherapy and HPV-driven tumors.
Source: Privo Technologies, Inc.
